Pulse Biosciences, Inc. PLSE
50.44 USD -1.81 (-3.46%)
Regular-session close
50.10 -0.34 -0.67%
After hours · Nov 13, 4:57 PM ET
50.23 Day range 54.25
12.66 52-week range 58.17
- YTD
- +267.37%
- 1 year
- +256.72%
News
benzinga.com Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $74 Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and raises the price target from $58 to $74.
benzinga.com Needham Maintains Buy on Pulse Biosciences, Raises Price Target to $64 Needham analyst Mike Matson maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and raises the price target from $58 to $64.
benzinga.com Pulse Biosciences Presents Six-Month Interim Results From PRECISE-BTN Thyroid Nodule Study, At 95th ATA Annual Meeting 86% of patients evaluated achieved at least 50% nodule volume reduction at six months after a single nonthermal nsPFA treatment, with significant improvements in symptoms and quality of life and no…
benzinga.com Pulse Biosciences Q3 2026 Earnings Call Transcript Pulse Biosciences (NASDAQ:PLSE) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…- benzinga.com Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Florida Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical dataPulse Biosciences, Inc. (NASDAQ:PLSE), the…
benzinga.com Oppenheimer Maintains Outperform on Pulse Biosciences, Raises Price Target to $60 Oppenheimer analyst Suraj Kalia maintains Pulse Biosciences (NASDAQ:PLSE) with a Outperform and raises the price target from $35 to $60.
benzinga.com Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $58 Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and raises the price target from $43 to $58.
benzinga.com TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
benzinga.com This HCA Healthcare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiated bullish coverage on HCA, GRDN, TTC, MRVL and PLSE, setting price targets of $495, $52, $120, $270 and $70.- benzinga.com BTIG Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $70 BTIG analyst Marie Thibault initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $70.
benzinga.com Pulse Biosciences Files Prospectus Supplement For Up To $85M At-The-market Common Stock Offering Via Mizuho; Terminates TD Cowen Distribution Agreement On Sept 14, 2026 With $1M Unsold On September 15, 2026, Pulse Biosciences, Inc. (the "Company") entered into an equity distribution agreement (the "Sales Agreement") with Mizuho Securities USA LLC ("Mizuho") as sales agent,- benzinga.com Pulse Biosciences Concludes 100 Patient Enrollment in PRECISE-BTN Study of nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced two milestones…
benzinga.com Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday U.S. stocks fell, but Wealthfront surged 6.6% after beating Q2 earnings and revenue estimates; Orchestra Biomed, Clover Health and AeroVironment also rose.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…- benzinga.com Freedom Capital Markets Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $73 Freedom Capital Markets analyst Keith Hinton initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $73.
benzinga.com Top 3 Health Care Stocks That May Keep You Up At Night In Q3 As of Aug. 27, 2026, three health care stocks are overbought and could be giving a real warning to momentum investors, according to the RSI indicator.
benzinga.com This Okta Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday Top Wall Street analysts changed their outlook on top stocks. See analyst ratings and price targets for PMT, ALAB.
benzinga.com This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday WALL analysts changed outlook on top names. See upgrades, downgrades & initiations on analyst ratings page. Workday downgraded, price target cut.
benzinga.com This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed outlook on top names. See analyst rating changes on Benzinga's page. Analysts have positive views on ONTO stock.- benzinga.com Needham Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $58 Needham analyst Mike Matson initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $58.
- benzinga.com Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $43 Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and raises the price target from $32 to $43.
- benzinga.com Pulse Biosciences Q2 EPS $(0.36), Inline, Sales $434.000K Miss $533.333K Estimate Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 28.57 percent decrease over losses of $(0.28) per share from the…
benzinga.com Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc…
benzinga.com Canaccord Genuity Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $32 Canaccord Genuity analyst William Plovanic initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $32.- benzinga.com Pulse Biosciences Co‑Chairmen, CEO Purchase ~$13.3M In Shares Via ATM Program Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan…
benzinga.com Earnings Scheduled For May 4, 2026 - benzinga.com Pulse Biosciences Q1 EPS $(0.27) Beats $(0.32) Estimate, Sales $401.000K Beat $400.000K Estimate Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.32) by 12.9 percent. This is a 8 percent decrease over losses of…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Pulse Biosciences Enrolls First Patient In Its NANOPULSE-AF Study Of nPulse Cardiac Catheter System For Recurrent, Drug-Resistant, Symptomatic Paroxysmal Atrial Fibrillation The first seven patients in this study were treated at St. Bernards Medical Center in Jonesboro, Arkansas, under the leadership of Devi Nair, MD, Principal Investigator of the Arrhythmia Research…- benzinga.com Pulse Biosciences' Long-Term AFib Clinical Data Demonstrates that Nanosecond Pulsed Field Ablation Delivers Speed, Safety, And Long-Term Durable Efficacy For Atrial Fibrillation (AFib). Pulse Biosciences, Inc. (NASDAQ:PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and
- benzinga.com Pulse Biosciences Begins First Human Study Of New Device To Treat Small Thyroid Cancer Tumors Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first
benzinga.com Pulse Biosciences Q4 Earnings Report: What Investors Need to Know - benzinga.com Pulse Biosciences Q4 EPS $(0.26) Beats $(0.31) Estimate, Sales $264.000K Beat $250.000K Estimate Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 16.13 percent increase over losses of…
- benzinga.com Earnings Scheduled For February 19, 2026
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Strategy Posts Upbeat Q4 Results, Joins SunOpta, BILL Holdings, Mitek Systems And Other Big Stocks Moving Higher On Friday U.S. stocks were higher, with the Dow Jones index gaining more than 700 points on Friday.
benzinga.com Earnings Scheduled For November 5, 2025 - benzinga.com Earnings Scheduled For August 12, 2025
- benzinga.com Earnings Scheduled For May 8, 2025
- benzinga.com Earnings Scheduled For March 27, 2025
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- benzinga.com Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday
- benzinga.com Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- benzinga.com Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quarter financial results.
- benzinga.com Earnings Scheduled For March 28, 2024 Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
- benzinga.com Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart…
- benzinga.com Earnings Scheduled For November 13, 2023 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Axcella Health Inc. (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company announced it was granted a patent for long COVID fatigue treatment.